Real-World Study Confirms Adebrelimab Efficacy in Extensive-Stage Small Cell Lung Cancer
核心洞察
A retrospective study of 35 patients with extensive-stage small cell lung cancer (搜索) demonstrated that first-line adebrelimab therapy achieved a 62.8% objective response rate and median overall survival of 15.0 months.
The study identified key prognostic factors, with ECOG performance status ≥2 predicting inferior progression-free survival and elevated C-reactive protein (搜索) levels associated with worse overall survival outcomes.
Grade 3-4 adverse events occurred in 74.3% of patients, primarily hematologic toxicities including neutropenia (搜索) in 51.4% of cases, with two instances of myocarditis (搜索) observed.
A new real-world study provides compelling evidence for the effectiveness of adebrelimab, an anti-PD-L1 (搜索) immunotherapy, as first-line treatment for extensive-stage small cell lung cancer (搜索) (ES-SCLC (搜索)). The retrospective analysis of 35 patients demonstrated promising clinical outcomes that align with pivotal trial data, offering valuable insights into the drug's performance in routine clinical practice.
Clinical Outcomes Demonstrate Strong Efficacy
The study revealed an objective response rate (ORR) of 62.8% and disease control rate (DCR) of 77.1% among patients receiving adebrelimab-based therapy. Median progression-free survival reached 7.1 months (95% CI: 5.47–8.53), while median overall survival extended to 15.0 months (95% CI: 10.47–19.53). These outcomes represent a substantial improvement over historical platinum-etoposide (搜索) chemotherapy, which typically achieved median overall survival of 8–13 months.
The patient population included predominantly male patients (88.6%) with a median age of 72 years. Most patients (85.7%) had Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores of 0–1, while 51.4% presented with two or more metastatic sites, reflecting the advanced nature of their disease.
Prognostic Factors Identify High-Risk Patients
Multivariate analysis identified several independent predictors of clinical outcomes that could guide treatment decisions. ECOG PS ≥2 emerged as a significant predictor of inferior progression-free survival, with a hazard ratio of 9.446 (p=0.013). For overall survival, patients with two or more metastatic organs faced increased risk (HR=3.594, p=0.046), as did those with C-reactive protein (搜索) (CRP (搜索)) levels ≥5 mg/L (HR=3.337, p=0.044).
These findings provide clinicians with valuable biomarkers to identify patients who may require more intensive monitoring or alternative treatment approaches.
Safety Profile Requires Vigilant Monitoring
The safety analysis revealed that 74.3% of patients experienced grade 3–4 adverse events, with hematologic toxicities representing the primary concern. Neutropenia (搜索) affected 51.4% of patients, highlighting the need for careful blood count monitoring during treatment. Notably, the study documented two cases (5.7%) of myocarditis (搜索), a rare but serious cardiac adverse event that requires immediate attention.
Real-World Validation of Clinical Trial Results
The study's findings validate the efficacy demonstrated in phase III trials that established adebrelimab plus chemotherapy as a new standard of care for ES-SCLC (搜索). Despite the real-world cohort being older than typical clinical trial populations, the treatment outcomes remained consistent with controlled trial results, suggesting broad applicability across diverse patient populations.
The researchers concluded that adebrelimab demonstrates potentially promising efficacy in ES-SCLC (搜索), while emphasizing the importance of vigilant monitoring for both hematologic toxicity and rare cardiotoxicity. The identification of specific prognostic factors provides a framework for optimizing patient selection and management strategies in clinical practice.